ORDAN MARK S 4
4 · MEDNAX, INC. · Filed Aug 31, 2021
Insider Transaction Report
Form 4
ORDAN MARK S
DirectorChief Executive Officer
Transactions
- Exercise/Conversion
Common Stock
2021-08-30$17.65/sh+95,000$1,676,750→ 303,425 total - Exercise/Conversion
Employee Stock Option (right to buy)
2021-08-30$17.65/sh−95,000$1,676,750→ 455,331 totalExercise: $17.65Exp: 2023-10-10→ Common Stock (95,000 underlying) - Sale
Common Stock
2021-08-30$35.09/sh−95,000$3,333,550→ 208,425 total
Footnotes (3)
- [F1]Shares acquired upon exercise of Stock Options granted pursuant to Issuer's Amended and Restated 2008 Incentive Compensation Plan (the "Plan").
- [F2]The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions with prices ranging from $34.965 to $35.235 for a weighted average sales price of $35.09. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]Option to purchase shares of common stock granted on July 12, 2020 ("Grant Date") under the Plan that vested as follows: (i) 175,747 shares became exercisable when the Issuer's common stock price closed at $22 per share (or above) for 40 consecutive trading days before the third anniversary of the Grant Date (the "Performance End Date"); (ii) 181,160 shares became exercisable when the Issuer's common stock price closed at $25 per share (or above) for 40 consecutive trading days before the Performance End Date; and (iii) 193,424 shares became exercisable when the Issuer's common stock price closed at $29 per share (or above) for 40 consecutive trading days before the Performance End Date, in each case subject to the reporting person's Employment Agreement and provided that no option shares vested prior to the one-year anniversary of the Grant Date.